Quantitative proteomics reveals a broad ‐ spectrum antiviral property of ivermectin, benefiting for COVID ‐ 19 treatment
This study, to our knowledge, was the first to provide ivermectin-regulated virus-related pathways by quantitative SILAC proteomic analysis, which revealed a broad spectrum antiviral property of ivermectin. What's more exciting is that the ivermectin-regulated proteins identified included some reported proteins related to SARS-CoV-2, and this could help exploit potential ivermectin-related biomarkers and new mechanisms in the disease. treatment of SARS-CoV-2 infection. Combining ivermectin with other drugs could lead to a more favorable prognosis for patients with COVID-19. For example, a study hypothesized that the combination of hydroxychloroquine and ivermectin could show consistent and synergistic action for the treatment of COVID-19 (Patrì & Fabbrocini, 2020). We anticipate our findings to guide efforts to understand the molecular mechanisms underlying ivermectin used for the treatment of SARS-CoV-2 infection. In addition, our results provide insight into the development of ivermectin as an option for the treatment of COVID-19 in the context of PPPM research and practice.